China Suspends Two Leukemia Drugs (China)
This article was originally published in PharmAsia News
China's State Food and Drug Administration has announced it is suspending the sale of two drugs used to treat leukemia and rheumatoid arthritis. The drugs, methotrexate and cytarabin hydrochloride, became the subject of scrutiny after the release of information by the National Center for ADR Monitoring. Patients taking the two drugs experienced adverse side effects including impaired leg movement and urine retention. The Chinese results are only the latest of 12,500 accounts of undesirable reactions to methotrexate. (Click here for more - May Require Free Registration
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.